Repligen (NASDAQ:RGEN) Given Buy Rating at HC Wainwright
Repligen (NASDAQ:RGEN – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $180.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 38.04% from the stock’s previous close. […]
Repligen (NASDAQ:RGEN – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $180.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 38.04% from the stock’s previous close. […]
